ストックスクリーナーアプリを入手
421.04
0.59%
2.46
アフターアワーズ：
421.00
-0.04
-0.01%
前日終値:
$418.58
開ける：
$420.63
24時間の取引高:
429.82K
Relative Volume:
0.56
時価総額：
$18.99B
収益：
$3.08B
当期純損益:
$1.24B
株価収益率:
16.44
EPS:
25.6108
ネットキャッシュフロー:
$1.07B
1週間 パフォーマンス:
-2.69%
1か月 パフォーマンス:
-2.69%
6か月 パフォーマンス:
+44.50%
1年 パフォーマンス:
+20.76%
1日の値動き範囲:
$411.92
$422.39
1週間の範囲:
$411.92
$432.20
52週間の値動き範囲:
$266.98
$459.48
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
UTHR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
421.04 | 18.93B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
147.53 | 64.68B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.17 | 44.25B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.20 | 41.19B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.61 | 21.74B | 16.70B | -157.13M | 1.19B | -0.1446 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Underweight |
| 2025-09-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | アップグレード | Goldman | Sell → Neutral |
| 2024-02-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-12-05 | 開始されました | Goldman | Sell |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-20 | 繰り返されました | BofA Securities | Underperform |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Neutral |
| 2021-07-14 | アップグレード | Argus | Hold → Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-03-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 開始されました | BofA/Merrill | Underperform |
| 2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
| 2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | アップグレード | UBS | Sell → Neutral |
| 2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
| 2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 繰り返されました | Barclays | Underweight |
| 2018-01-18 | 再開されました | Credit Suisse | Underperform |
| 2017-12-27 | 繰り返されました | Wedbush | Outperform |
| 2017-04-27 | 繰り返されました | Wedbush | Outperform |
| 2017-03-30 | 開始されました | UBS | Sell |
| 2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
United Therapeutics’ Xenokidney Study: A New Hope for ESRD Patients - TipRanks
United Therapeutics’ DeciPHer-ILD Study: A Closer Look at PH-ILD Patient Registry - TipRanks
United Therapeutics’ PHINDER Study: A Step Forward in Early Detection of Pulmonary Hypertension - TipRanks
United Therapeutics Advances Ralinepag Study for PAH Treatment - TipRanks
Will United Therapeutics Corporation stock benefit from upcoming earnings reports2025 Risk Factors & Reliable Breakout Forecasts - newser.com
What margin trends mean for United Therapeutics Corporation stockMarket Growth Review & Consistent Profit Trading Strategies - newser.com
Nepsis Liquidates $14 Million CyberArk Software (NASDAQ: CYBR) Position: Did the Stock Soar Too High, Too Fast? - The Motley Fool
Published on: 2025-10-26 13:21:57 - newser.com
Will United Therapeutics Corporation benefit from macro trendsMarket Weekly Review & Precise Swing Trade Alerts - newser.com
How United Therapeutics Corporation (UTH) stock benefits from digital adoptionJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
What data driven models say about United Therapeutics Corporation’s future2025 Sector Review & Fast Moving Stock Watchlists - newser.com
Risk adjusted return profile for United Therapeutics Corporation analyzedJuly 2025 Volume & Fast Gain Swing Trade Alerts - newser.com
What makes United Therapeutics Corporation stock attractive to growth fundsTrade Risk Assessment & Precise Trade Entry Recommendations - newser.com
United Therapeutics Executives Sell Shares - TradingView
United Therapeutics EVP & General Counsel Sells 11,000 Shares - TradingView
Why United Therapeutics Corporation (UTH) stock gets analyst attention2025 Buyback Activity & Reliable Momentum Entry Alerts - newser.com
United Therapeutics Corporation (UTHR) Stock forecasts - Yahoo
Will United Therapeutics Corporation (UTH) stock attract long term capital inflowsJuly 2025 Setups & Weekly High Potential Alerts - Trung tâm Dự báo KTTV quốc gia
Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case - Insider Monkey
United Therapeutics CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
PH-ILD hospitalization data on inhaled treprostinil — United Therapeutics at CHEST 2025 - Stock Titan
Callan Family Office LLC Increases Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (FRA:UTH) Gross-Profit-to-Asset % : 35.18% (As of Jun. 2025) - GuruFocus
UTHR (United Therapeutics) Cyclically Adjusted PB Ratio : 4.79 (As of Oct. 12, 2025) - GuruFocus
Inspire Investing LLC Trims Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
UTHR (United Therapeutics) 5-Year RORE % : 17.31% (As of Jun. 2025) - GuruFocus
UTHR (United Therapeutics) Revenue per Share : $63.53 (TTM As of Jun. 2025) - GuruFocus
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp. Hits New 52-Week High of $455.26 - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High of $459.48 - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High of $455.00 - Markets Mojo
United Therapeutics (NASDAQ:UTHR) Sets New 52-Week HighHere's What Happened - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
QRG Capital Management Inc. Raises Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Is There Still an Opportunity in United Therapeutics After Its 25.8% Year to Date Surge? - simplywall.st
Polaris Capital Management LLC Reduces Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Hilltop National Bank Takes $341,000 Position in United Therapeutics Corporation $UTHR - MarketBeat
What Catalysts Are Reshaping the Narrative for United Therapeutics This Year? - Yahoo Finance
A Look at United Therapeutics (UTHR) Valuation as Tyvaso Shows Breakthrough Results in Late-Stage IPF Trial - simplywall.st
How Positive TETON-2 Results for Tyvaso Have Changed United Therapeutics' (UTHR) Investment Story - simplywall.st
News impact scoring models applied to United Therapeutics CorporationPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Robeco Institutional Asset Management B.V. Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock hits all-time high at 442.02 USD - Investing.com
United Therapeutics stock hits all-time high at 442.02 USD By Investing.com - Investing.com South Africa
United Therapeutics rides Tyvaso optimism as IPF trial gains momentum - S&P Global
TD Cowen maintains Buy rating on United Therapeutics stock, citing IPF opportunity - Investing.com
Jefferies reiterates Buy rating on United Therapeutics stock amid patent case - Investing.com
UBS maintains United Therapeutics stock Buy rating amid patent litigation By Investing.com - Investing.com Canada
United Therapeutics COO sells $9.49m in UTHR stock By Investing.com - Investing.com South Africa
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
3.48%
0.75%
大文字化:
|
ボリューム (24 時間):